Diroximel fumarate for treating relapsing–remitting multiple sclerosis

2.1 Diroximel fumarate (Vumerity, Biogen) has a marketing authorisation 'for the treatment of adult patients with relapsing–remitting multiple sclerosis'.

2.2 The dosage schedule is available in the summary of product characteristics for diroximel fumarate.

2.3 The list price of diroximel fumarate is £1,471.07 per pack (231 mg, 120 capsules; excluding VAT; price as quoted in the company's submission).

2.4 The company has a commercial arrangement. This makes diroximel fumarate available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.